Navigation Links
Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Date:2/8/2013

enues under the Company's elagolix collaboration agreement. Revenues for the year ended December 31, 2012 were $53.1 million, compared with $77.4 million for 2011. The $24.3 million decrease in revenue is primarily due to $30 million in milestones achieved under the Company's elagolix collaboration agreement during the third quarter of 2011.

Research and development expenses increased to $9.1 million during the fourth quarter of 2012 compared with $8.0 million for the same period in 2011. For the year ended December 31, 2012, research and development expenses were $37.2 million, compared to $31.0 million for 2011. The increase in research and development expenses is primarily driven by Phase IIb development expenses for the VMAT2 program, coupled with increased compensation related costs, primarily due to equity based compensation.

General and administrative expenses increased to $3.3 million during the fourth quarter of 2012 compared with $2.7 million for the same period last year. For the year ended December 31, 2012, general and administrative expenses were $13.4 million, compared to $12.5 million for 2011. The increase in year-to-date general and administrative expenses is primarily related to higher equity based compensation costs.

2013 Financial GuidanceThe Company expects to have a net cash burn from operations of approximately $50 to $55 million in 2013. Revenue is expected to approximate $3 million which consists solely of the amortization of up-front license fees. Expenses for 2013 should approximate $55 to $60 million. Net loss for 2013 is expected to be $50 to $55 million, or $0.75 to $0.83 loss per share based on 66.5 million basic shares outstanding. The Company expects to end 2013 with in excess of $130 million in cash, investments and receivables.

Pipeline HighlightsElagolix UpdateAbbVie is currently conducting the initial Phase III study of elagolix for endometriosis, the Violet Petal Study. The study is a 24-week
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Neurocrine Biosciences Reports Third Quarter 2012 Results
3. Neurocrine Biosciences Reports Second Quarter 2012 Results
4. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
5. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
9. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... use light, rather than electricity, to move data ... efficiency is a growing concern as chips, transistor ... of optical circuits light emitters, modulators, and ... One promising light source for optical chips is ... when deposited as a single, atom-thick layer. Other ...
(Date:9/19/2014)... , September 19, 2014 ... technology, development of emerging drug systems and advanced Laboratory ... Dickinson and Company (NYSE: BDX ), Thermo ... Biosciences Inc. (NASDAQ: RGDO ), Sangamo Biosciences ... (NASDAQ: HOLX) Pressure BioSciences, Inc. (OTCQB: PBIO) ...
(Date:9/19/2014)... 2014 BioTech News Coverage: Progress ... results of studies and trials.  Companies in focus are: ... LLY ), Gilead Sciences Inc. (NASDAQ: ... ) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) ... therapeutics for the treatment of cancer, announced that the ...
(Date:9/19/2014)... 2014 Dublin ... has announced the addition of the  "Micro Market ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... the fastest-growing segments in the chromatography market. The ... and expected to reach $2.0 billion by 2019, ...
Breaking Biology Technology:Toward optical chips 2Toward optical chips 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 4Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 5Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 6Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 7Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7Micro Market Monitor : Global Pre-packed Chromatography Columns 2
... Council has teamed with JobSightUSA , a top-ranked ... match job seekers with positions based on specific "skill ... that are considering locating or expanding in Wisconsin to ... Wisconsinite workers who may wish to return to the ...
... plugs, cut the cords, and can the cables as we ... for all the freedom and mobility, we are nowhere without ... the like. That fact alone has turned the average business ... most obscure corner of airports and coffee houses. Indeed, Im ...
... 2004, the New Venture Center at the Fitchburg ... in its first phase. , ,Ground-breaking will be held on ... tenant is another nanotech company, Imago Scientific . When it ... to staff up to 71 over the next eight months. , ...
Cached Biology Technology:Power for the people 2Fitchburg Technology Campus attracts nanotechnology firms 2
(Date:9/22/2014)... robots could be much more useful in homes, if ... usually see the world with cameras and lasers, which ... that are hidden in clutter. A complementary way robots ... use of small ultra-high frequency radio-frequency identification (UHF RFID) ... allowing an RFID-equipped robot to search a room for ...
(Date:9/22/2014)... 2014 NXT-ID, Inc. (NASDAQ: NXTD ... mobile commerce market, issues the following corporate shareholder update ... Letter from the CEO : ... funding and joined the NASDAQ to support ramping of ... biometric and authentication products and services. This strategic achievement positions ...
(Date:9/21/2014)... September 22, 2014The story of cowpea (black-eyed peas) is ... world,s biggest problemseven more fascinating is the story of ... wrote Cowpea: The Food Legume of the 21st Century ... management, and use. The book was recently published by ... International Institute of Tropical Agriculture (IITA). , Singh has ...
Breaking Biology News(10 mins):New RFID technology helps robots find household objects 2New RFID technology helps robots find household objects 3NXT-ID Issues Shareholder Corporate Update 2NXT-ID Issues Shareholder Corporate Update 3NXT-ID Issues Shareholder Corporate Update 4
... Bellvitge Biomedical Research Institute (IDIBELL) have shown that breast ... higher level of the protein peroxiredoxin 2 (PRDX2). The ... this protein could be a new therapeutic strategy to ... in the online edition of the journal Oncogene ...
... Researchers have gained new insight into why 22% ... a folate concentration considered optimal for reducing the risk of ... of folate deficiency in the general Canadian population. When ... reason why some women are not achieving levels optimal for ...
... April 10, 2012 The neighborhoods in which children and ... whether or not they eat a healthy diet, get enough ... a special theme issue of the American Journal of ... uses the latest concepts and methods in geographic information systems ...
Cached Biology News:Geographic information systems demonstrate links between health and location 2
... is the complete enterprise microarray informatics platform for ... Buy Acuity once and use it forever without ... for Quality Acuity has all the analysis ... your data, from quality control statistics and normalization, ...
... workstation offers precise 96 and 384-well transfers ... 100ul and 200ul disposable tips, the 96 ... and precision across a volume range from ... two positions that enable indexing into 384 ...
... ideal instrument for budget-conscious labs that want to ... Get Applied Biosystems proven PCR performance at ... without sacrificing results. Enhance productivity with ... Can Afford The Applied Biosystems 2720 ...
... to Salmonella typhimurium The genus Salmonella is ... is composed of Gram-negative bacilli that are facultative ... the "H" or flagellar antigen (phase 1 & ... the LPS moiety) and the "Vi" or capsular ...
Biology Products: